Literature DB >> 12702573

Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells.

Guo-Qiang Chen1, Li Zhou, Miroslav Styblo, Felecia Walton, Yongkui Jing, Rona Weinberg, Zhu Chen, Samuel Waxman.   

Abstract

Treatment with arsenic trioxide (As(2)O(3)) by inducing apoptosis and partial differentiation of acute promyelocytic leukemia (APL) cells results in clinical remission in APL patients resistant to chemotherapy and all-trans-retinoic acid. As(2)O(3) (iAs(III)) is methylated in the liver to mono- and dimethylated metabolites, including methylarsonic acid, methylarsonous acid, dimethylarsinic acid, and dimethylarsinous acid. Methylated trivalent metabolites that are potent cytotoxins, genotoxins, and enzyme inhibitors may contribute to the in vivo therapeutic effect of iAs(III). Therefore, we compared the potency of iAs(III) and trivalent metabolites using chemical precursors of methylarsonous acid and dimethylarsinous acid to induce differentiation, growth inhibition, and apoptosis. Methylarsine oxide (MAs(III)O) and to a lesser extent iododimethylarsine were more potent growth inhibitors and apoptotic inducers than iAs(III) in NB4 cells, an APL cell line. This was also observed in K562 human leukemia, lymphoma cell lines, and in primary culture of chronic lymphocytic leukemia cells, but not human bone marrow progenitor cells. Apoptosis was associated with greater hydrogen peroxide accumulation and inhibition of glutathione peroxidase activity. MAs(III)O, in contrast to iAs(III), did not induce PML-retinoic acid receptor alpha degradation, or restore PML nuclear bodies or differentiation in NB4 cells. In a cocultivation experiment, hepatoma-derived HepG2 cells, but not NB4 cells, methylate radiolabeled iAs(III). Methylated metabolites released from HepG2 cells are preferentially accumulated by NB4 cells. This experimental model suggests that in vivo hepatic methylation of iAs(III) may contribute to As(2)O(3)-induced apoptosis but not differentiation of APL cells. MAs(III)O as an apoptotic inducer should be considered in the treatment of other hematologic malignancies like lymphoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12702573

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Biography of Zhu Chen.

Authors:  David Bradley
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-05       Impact factor: 11.205

2.  Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer.

Authors:  Junqiang Tian; Hongjuan Zhao; Rosalie Nolley; Stephen W Reese; Sarah R Young; Xuejun Li; Donna M Peehl; Susan J Knox
Journal:  Clin Cancer Res       Date:  2012-04-25       Impact factor: 12.531

Review 3.  Arsenic trioxide - An old drug rediscovered.

Authors:  Ashkan Emadi; Steven D Gore
Journal:  Blood Rev       Date:  2010-05-15       Impact factor: 8.250

Review 4.  Double-Sided Personality: Effects of Arsenic Trioxide on Inflammation.

Authors:  Juan Zhang; Yue Zhang; Weiyan Wang; Chunling Li; Zhiyi Zhang
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

Review 5.  From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia.

Authors:  Sai-Juan Chen; Guang-Biao Zhou; Xiao-Wei Zhang; Jian-Hua Mao; Hugues de Thé; Zhu Chen
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

6.  The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells.

Authors:  Xiaodong Cheng; Alfonso Quintás-Cardama; Mirna Golemovic; Ralph Zingaro; Ming-Zhang Gao; Emil J Freireich; Michael Andreeff; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Anticancer Res       Date:  2012-07       Impact factor: 2.480

7.  A novel MAs(III)-selective ArsR transcriptional repressor.

Authors:  Jian Chen; Venkadesh Sarkarai Nadar; Barry P Rosen
Journal:  Mol Microbiol       Date:  2017-09-13       Impact factor: 3.501

8.  Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1.

Authors:  Rui Wang; Changda Liu; Lijuan Xia; Guisen Zhao; Janice Gabrilove; Samuel Waxman; Yongkui Jing
Journal:  Clin Cancer Res       Date:  2012-10-18       Impact factor: 12.531

9.  MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells.

Authors:  Mirna Golemovic; Alfonso Quintás-Cardama; Taghi Manshouri; Nada Orsolic; Hatice Duzkale; Mary Johansen; Emil J Freireich; Hagop Kantarjian; Ralph A Zingaro; Srdan Verstovsek
Journal:  Invest New Drugs       Date:  2009-05-26       Impact factor: 3.850

Review 10.  Current first- and second-line treatment options in acute promyelocytic leukemia.

Authors:  Fulvio Massaro; Matteo Molica; Massimo Breccia
Journal:  Int J Hematol Oncol       Date:  2017-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.